Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment

BACKGROUND: Cabotegravir (CAB) is an integrase inhibitor in phase 3 clinical trials for the treatment and prevention of HIV. CAB undergoes glucuronidation via UGT1A1 with <1% renal elimination of unchanged CAB. Renal impairment may affect PK of drugs that are primarily metabolized or secreted in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Open Forum Infect Dis
Huvudupphovsmän: Parasrampuria, Ridhi, Ford, Susan, Lou, Yu, Fu, Caifeng, Bakshi, Kalpana, Tenorio, Allan, Trezza, Christine, Spreen, William, Patel, Parul
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2017
Ämnen:
Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5631309/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1085
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk